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Abstract
Background
AU
Hypertension
: Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly:
treatment reduces morbidity and mortality yet has not been broadly implemented in many low-resource settings, including sub-Saharan Africa (SSA). We hypothesized that a patient-centered integrated chronic disease model that included hypertension
treatment and leveraged the HIV care system would reduce mortality among adults with
uncontrolled hypertension in rural Kenya and Uganda.

Methods and findings
This is a secondary analysis of the SEARCH trial (NCT:01864603), in which 32 communities
underwent baseline population-based multidisease testing, including hypertension screening, and were randomized to standard country-guided treatment or to a patient-centered
integrated chronic care model including treatment for hypertension, diabetes, and HIV.
Patient-centered care included on-site introduction to clinic staff at screening, nursing triage
to expedite visits, reduced visit frequency, flexible clinic hours, and a welcoming clinic environment. The analytic population included nonpregnant adults (�18 years) with baseline
uncontrolled hypertension (blood pressure �140/90 mm Hg). The primary outcome was 3year all-cause mortality with comprehensive population-level assessment. Secondary outcomes included hypertension control assessed at a population level at year 3 (defined per
country guidelines as at least 1 blood pressure measure <140/90 mm Hg on 3 repeated
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Community-randomized trial of patient-centered integrated hypertension and HIV care in Kenya and Uganda

measures). Between-arm comparisons used cluster-level targeted maximum likelihood
estimation.
Among 86,078 adults screened at study baseline (June 2013 to July 2014), 10,928 (13%)
had uncontrolled hypertension. Median age was 53 years (25th to 75th percentile 40 to 66);
6,058 (55%) were female; 677 (6%) were HIV infected; and 477 (4%) had diabetes mellitus.
Overall, 174 participants (3.2%) in the intervention group and 225 participants (4.1%) in the
control group died during 3 years of follow-up (adjusted relative risk (aRR) 0.79, 95% confidence interval (CI) 0.64 to 0.97, p = 0.028). Among those with baseline grade 3 hypertension
(�180/110 mm Hg), 22 (4.9%) in the intervention group and 42 (7.9%) in the control group
died during 3 years of follow-up (aRR 0.62, 95% CI 0.39 to 0.97, p = 0.038). Estimated population-level hypertension control at year 3 was 53% in intervention and 44% in control communities (aRR 1.22, 95% CI 1.12 to 1.33, p < 0.001). Study limitations include inability to
identify specific causes of death and control conditions that exceeded current standard
hypertension care.

Conclusions
In this cluster randomized comparison where both arms received population-level hyperten-

Abbreviations: AU
aRR,: adjusted
Anabbreviationlisthasbeencompiledforthoseusedthroughoutthetext:Pleaseverifythatallentriesarecorrect:
relative risk; BMI,
sion screening, implementation of a patient-centered hypertension care model was associbody mass index; CI, confidence interval; CVD,
ated with a 21% reduction in all-cause mortality and a 22% improvement in hypertension
cardiovascular disease; DALY, disability-adjusted
life year; NCD, noncommunicable disease;
control compared to standard care among adults with baseline uncontrolled hypertension.
SEARCH, Sustainable East Africa Research in
Patient-centered chronic care programs for HIV can be leveraged to reduce the overall burCommunity Health; SSA, sub-Saharan Africa;
den of cardiovascular mortality in SSA.
TMLE, targeted maximum likelihood estimation.

Trial registration
ClinicalTrials.gov NCT01864603.

Author summary
Why was this study done?
• There is a growing burden of hypertension and resultant cardiovascular disease (CVD)
globally, and particularly in sub-Saharan Africa (SSA).
• Maintenance of normal blood pressure through treatment with antihypertensive medications clearly reduces CVD morbidity and mortality; yet across SSA, only 28% are
aware of their hypertension diagnosis, only 18% are on treatment, and only 7% have
controlled blood pressure.
• The HIV chronic care system offers a platform for integrating noncommunicable disease (NCD) care for both people with HIV and the general population, though there are
limited data on the implementation and effectiveness of such care models.

PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003803 September 20, 2021

2 / 21

PLOS MEDICINE

Community-randomized trial of patient-centered integrated hypertension and HIV care in Kenya and Uganda

What did the researchers do and find?
• We conducted a secondary analysis of data from the SEARCH cluster randomized controlled trial in 32 communities in Kenya and Uganda where all communities received
population-wide hypertension and multidisease screening and were randomized to
standard country-guided treatment or to a patient-centered integrated chronic care
model including treatment for hypertension, diabetes, and HIV.
• Among 86,078 nonpregnant adults screened at baseline, we identified 10,928 (13%)
with uncontrolled hypertension, all of whom were referred to the nearest governmentrun health facility for hypertension care.
• We conducted comprehensive vital status assessment after 3 years, determining vital status for 99% of participants. Among adults with baseline uncontrolled hypertension, allcause mortality was 21% lower in intervention compared to control communities (3.1%
versus 4.2%).

What do these findings mean?
• Providing hypertension care through an integrated, patient-centered chronic care
model was associated with a 21% reduction in all-cause mortality over 3 years among
patients with uncontrolled hypertension at study baseline.
• Though the intervention was associated with improved hypertension control, half of
participants remained uncontrolled, attenuating the benefits of hypertension treatment.
Strategies to improve linkage and engagement in hypertension care are likely to further
improve treatment outcomes in the context of integrated patient-centered hypertension
care models.
• Leveraging the HIV care platform is a promising strategy for delivering chronic hypertension and other NCD care to address the growing burden of NCDs in SSA.

Introduction
Hypertension is the most important risk factor for cardiovascular disease (CVD) and accounts
for 14% of global mortality [1]. In sub-Saharan Africa (SSA), the prevalence of hypertension
has been steadily increasing [2,3], contributing to a significant rise in CVD-associated mortality [4]. Despite rising prevalence in SSA, population-based surveys demonstrate substantial
inequity in hypertension control compared to other regions [5], with only one-quarter of
adults with hypertension aware of their diagnosis, 18% receiving treatment, and 7% achieving
hypertension control [6]. Although there is a strong evidence base that hypertension treatment
decreases the incidence of CVD and reduces mortality [7,8], this evidence has not been translated into practice in SSA.
In contrast to limited implementation of hypertension treatment, the HIV response has created a broad chronic care delivery system across much of SSA, providing a clear opportunity
to leverage this infrastructure for other high-burden chronic diseases [9,10]. Several studies
have evaluated interventions to improve integration of hypertension treatment with HIV care;
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however, these approaches have had limited impact on hypertension treatment outcomes [11–
16].
The Sustainable East Africa Research in Community Health (SEARCH) study was a cluster
randomized trial in Kenya and Uganda designed to evaluate a universal test and treat strategy
on HIV incidence and community health outcomes [17]. SEARCH conducted populationlevel screening for hypertension and HIV at study baseline, reaching 90% of the census-enumerated adult population for HIV testing and 70% for hypertension screening [17,18]. In
intervention communities, SEARCH implemented a patient-centered, streamlined care delivery model for integrated noncommunicable disease (NCD) and HIV care [19,20]. Previously
published analyses of prespecfied trial outcomes demonstrated that this community-level
intervention reduced HIV-associated mortality and improved population-level viral suppression [17]. In this analysis, our objective was to evaluate the effect of the SEARCH patient-centered, streamlined care intervention on mortality and hypertension care cascade outcomes
among adults with uncontrolled hypertension identified at baseline population-level
screening.

Methods
Study setting and population
The SEARCH study (NCT:01864603) was a pair-matched cluster randomized controlled trial
in 32 rural communities Kenya and Uganda conducted over 3 years from 2013 to 2017 [17].
At baseline, we conducted a community-wide census to enumerate residents in each of the 32
communities, followed by 2-week community health campaigns that offered screening for
HIV, hypertension, and diabetes [21]. Community health campaigns were held again in all
communities after 3 years of follow-up and annually in intervention communities. This study
is reported according to the Consort Statement for cluster randomized trials (S1 Consort
Checklist).
At community health campaigns, hypertension screening was conducted using an algorithm based on WHO/International Society of Hypertension guidelines (S1 File) [22]. Using
an electronic sphygmomanometer, all adults �18 years had a single blood pressure measurement. Those with an elevated initial blood pressure (systolic �140 mm Hg or diastolic �90
mm Hg) had 2 repeat measurements separated by at least 1 minute of rest. A diagnosis of
uncontrolled hypertension was made if systolic blood pressure was �140 mm Hg or diastolic
blood pressure �90 mm Hg on all measurements, per contemporary WHO guidelines [22].
Diabetes screening was also conducted among adults with risk factors or symptoms of hyperglycemia using random fingerstick glucose measurement; diagnosis was based on random glucose >11 mmol/L or self-reported history of diabetes (S2 File). Our population for this study
included nonpregnant adults (age �18 years) with uncontrolled hypertension identified
through baseline screening.

Linkage to care
In all 32 communities, participants diagnosed with uncontrolled hypertension at baseline were
scheduled for an appointment at the nearest government-run health center within each community. Individuals with comorbid HIV infection additionally received a 1-time transportation voucher to facilitate linkage to care. In intervention communities, additional strategies
were implemented to facilitate linkage. First, at community health campaigns, patients were
introduced to a clinic staff member, in person or by phone, and were given a phone number to
call with questions. Second, individuals with comorbid HIV infection who missed their initial
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clinic appointment received a phone call or, if the phone call was unsuccessful, a home visit to
reschedule their appointment [23].

Streamlined hypertension care intervention
The SEARCH patient-centered streamlined care model focused on reducing structural barriers
to care and improving relationships between patients and clinic, as described previously
[19,20]. Hypertension, diabetes, and HIV treatment were provided using an integrated care
model, which featured a nurse-driven triage system to tailor visits based on patient need and
reduce waiting time, flexible clinic hours, phone-based appointment reminders, telephone
access to clinicians, and a welcoming environment with clinicians and staff trained on providing friendly services. Blood pressure medications were prescribed for 12 weeks when hypertension was controlled (<140/90 mm Hg) and for 4 weeks when uncontrolled, using standardized
protocols adapted from national guidelines (S1 File) [19]. Treatment for those with comorbid
diabetes was also provided using a country guideline-based algorithm (S2 File). Clinic medication supplies were supplemented by the study, and medications were provided free of charge.
Clinicians received initial training on treatment algorithms and streamlined care, followed by
refresher trainings and on-site mentoring approximately 3 to 4 times per year during the study.
Both HIV-uninfected and HIV-infected individuals received care using the same streamlined
model. For people with HIV and hypertension, care was delivered during the same visit, with
both HIV and hypertension medications provided during clinical consultation.

Control hypertension care
In control communities, NCD care was provided at the general outpatient department in larger
clinics and at the HIV clinic at smaller clinics. To reduce the possibility that differential clinic
staffing would be the primary driver of outcomes, clinics in control communities were provided
with similar staffing to that of intervention clinics, generally a clinical officer and nurse at each
clinic. Hypertension and diabetes treatment was administered using the same treatment guidelines as in the intervention; clinic medication supplies were supplemented by the study, and
medications were provided free of charge. Clinicial staff received initial training on treatment
algorithms and referesher trainings approximately twice per year during the study.

Outcome measurement and definition
Vital status was assessed during a repeat community health campaign conducted in each community at year 3. Individuals who were not seen at year 3 community health campaigns were
tracked to ascertain vital status from the individual or via interview with a household member,
neighbor, or community leader [17].
At baseline and year 3, hypertension was classified according to the lowest measured blood
pressure, described above, as controlled (<140/90 mm Hg), grade 1 (140 to 159/90 to 99 mm
Hg), grade 2 (160 to 179/100 to 109 mm Hg), or grade 3 (�180/110 mm Hg) [22]. Since participation in community health campaigns was independent from linkage and retention in care,
blood pressure assessment in this study did not rely on clinic measures.
We defined linkage to hypertension care as �1 clinic visit during the first year of follow-up
and engagement in hypertension care as �1 clinic visit during each year of follow-up.

Statistical analysis
This was a secondary analysis of prespecified outcomes in the SEARCH trial (mortality, hypertension control, linkage, and engagement) among persons with baseline uncontrolled
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hypertension. Statistical analyses were conducted using a prespecified analysis plan (S1 Statistical Analysis Plan). As previously detailed [17,24], sample size and power calculations were
conducted for the trial’s primary outcome, HIV incidence, and communities were randomized
to the intervention or control condition within matched pairs.
We evaluated the effect of the SEARCH intervention on 3-year mortality among nonpregnant adults (age �18 years) with uncontrolled hypertension identified at baseline populationlevel screening. To do so, we compared mortality by follow-up year 3 between intervention
and control communities using a 2-staged approach, accounting for clustering and the
matched-pair design [17,24]. We first calculated the proportion of participants in each community who died by year 3, excluding persons whose year 3 vital status was unknown. We
then compared mortality between study arms using community-level targeted maximum likelihood estimation (TMLE) with cross-validation to select baseline adjustment variables from
the following prespecified set: the proportion of participants aged �60 years and the proportion of participants with grade 2 or greater hypertension severity [25]. In sensitivity analyses,
we excluded persons aged �80 years given that hypertension treatment may be deferred in
some elderly individuals, and persons with baseline HIV infection to isolate the effect of
improved hypertension care from effects due to improvement in HIV care.
We used a similar 2-stage procedure to evaluate the effect of the intervention on population-level hypertension control at year 3 (lowest blood pressure <140/90 mm Hg), using
TMLE to adjust for differences in characteristics between persons with measurements and persons with missing measurements [17,24,26]. Additionally, we reported changes in grade of
hypertension severity and median reduction in systolic blood pressure between baseline and
year 3.
To understand intervention impacts on distinct components of the hypertension care cascade, we compared the proportions who attained each step in the hypertension care cascade
(linkage, engagement, and hypertension control) at year 3 using the 2-stage approach. Due to
limitations of clinic visit data for hypertension care in Kenya, this analysis included only the 10
intervention and 10 control communities in Uganda.
To understand heterogeneity in intervention effects, we repeated analyses of each outcome
stratifying on sex and baseline hypertension severity. We also conducted post hoc stratification
of results by country.
Finally, to understand the risk factors for mortality, hypertension control, and linkage to
care among adults with baseline uncontrolled hypertension, we assessed the following individual-level predictors: age, sex, baseline hypertension severity, body mass index (BMI) category,
HIV status, and diabetes status. We used TMLE to obtain adjusted relative risks (aRRs) for
each predictor accounting for clustering by community.

Ethical considerations
The study was approved by the Makerere University School of Medicine Research and Ethics
Committee, the Uganda National Council for Science and Technology, the Kenya Medical
Research Instittue Ethical Review Committee, and the University of California San Francisco
Committee on Human Research. Verbal informed consent was obtained for all participants at
study enrollment.

Results
Study population
We conducted baseline hypertension screening in 86,078 (68%) of 126,311 census-enumerated
nonpregnant adults �18 years of age, 44,717 (67%) in intervention communities and 41,361
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Fig 1. Study flow diagram. Baseline and year 3 BP was measured at CHCs. Vital status was measured in all study participants
regardless of CHC participation. BPAU
, blood
: TheabbreviationlistsinFigs1
pressure; CHC, community health
6havebeenupdated:Pleaseverifythattheaddedentriesarecorrect:
campaign; HTN, hypertension; yr3, year 3.
https://doi.org/10.1371/journal.pmed.1003803.g001

(69%) in control communities (Fig 1). Baseline characteristics of the screened adult population
and those with uncontrolled hypertension were similar between intervention and control communities (Tables A and B in S1 Tables, Table 1). Of those screened, 12% in intervention communities (n = 5,459) and 13% in control communities (n = 5,469) had uncontrolled
hypertension and were included in analysis.
Among 10,928 participants with baseline uncontrolled hypertension, 55% were women
(n = 6,058) and median age was 53 years (25th to 75th percentile 40 to 66). Only 13% reported
a prior diagnosis of hypertension (n = 1,460), 53% of whom reported current hypertension
treatment (n = 777). The majority had grade 1 hypertension (69%, n = 7,585), 22% had grade 2
hypertension (n = 2,359), and 9% had grade 3 hypertension (n = 984). About 4% had comorbid
diabetes (n = 477), and 6% had comorbid HIV (n = 677); among whom baseline CD4 count
was <350 cells/mL in 23% (n = 156), 350 to 499 cells/mL in 23% (n = 155), �500 cells/mL in
52% (n = 355), and missing in 2% (n = 11). Baseline HIV viral suppression (<500 copies/mL)
among those with a measured viral load was 59% (306/521).
Compared to males, females with baseline uncontrolled hypertension were older (43% age
�60 [2,589/6,058] versus 33% for males [1,601/4,870]), had more severe hypertension (35%
with grade 2 or greater [2,113/6,058] versus 25% for males [1,230/4,870]), more likely to report
a prior diagnosis of hypertension (18% [1,061/6,058] versus 9% [399/4,870]), and more likely
to be obese (10% [581/6,058] versus 3% [135/4,870]) (Table C in S1 Tables).

Mortality
Vital status at year 3 was ascertained in 99% of participants in both intervention communities
(5,422/5,459) and control communities (5,426/5,469) (Fig 1). A total of 399 participants died
over the 3 years of follow-up, 174 in intervention communities and 225 in control communities. Three-year cumulative mortality risk was 3.2% (174/5,422) in the intervention arm and
4.1% (225/5,426) in the control arm, corresponding to a 21% reduction in 3-year mortality in

PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003803 September 20, 2021

7 / 21

PLOS MEDICINE

Community-randomized trial of patient-centered integrated hypertension and HIV care in Kenya and Uganda

Table 1. Baseline characteristics of nonpregnant adults with baseline uncontrolled hypertension.
Intervention

Control

Overall

n = 5,459

n = 5,469

n = 10,928

n

%

n

%

n

%

Region
Eastern Uganda

2,117

39%

2,136

39%

4,253

39%

Kenya

1,347

25%

1,439

26%

2,786

25%

Western Uganda

1,995

37%

1,894

35%

3,889

36%

Female

3,037

56%

3,021

55%

6,058

55%

Male

2,422

44%

2,448

45%

4,870

45%

18–29 years

630

12%

679

12%

1,309

12%

30–44 years

1,195

22%

1,117

20%

2,312

21%

45–59 years

1,549

28%

1,568

29%

3,117

29%

60–74 years

1,440

26%

1,448

26%

2,888

26%

�75 years

645

12%

657

12%

1,302

12%

First, indicating least wealth

933

17%

1,033

19%

1,966

18%

Second

902

17%

982

18%

1,884

17%

Third

1,088

20%

1,086

20%

2,174

20%

Fourth

1,178

22%

1,205

22%

2,383

22%

Fifth, indicating most wealth

1,329

24%

1,111

20%

2,440

22%

Missing

29

1%

52

1%

81

1%

Self-reported prior HTN diagnosis

690

13%

770

14%

1,460

13%

Self-reported baseline HTN treatment

364

7%

413

8%

777

7%

Grade 1 (140–159/90–99)

3,810

70%

3,775

69%

7,585

69%

Grade 2 (160–179/100–109)

1,197

22%

1,162

21%

2,359

22%

Grade 3 (�180/110)

452

8%

532

10%

984

9%

Underweight (<18.5)

836

15%

807

15%

1,643

15%

Healthy weight (18.5–24.9)

3,288

60%

3,205

59%

6,493

59%

Overweight (25.0–29.9)

946

17%

1,040

19%

1,986

18%

Obese (�30)

368

7%

348

6%

716

7%

Missing

21

0%

69

1%

90

1%

HIV

357

7%

320

6%

677

6%

Diabetes

227

4%

250

5%

477

4%

Sex

Age category

Wealth quintile categories�

Baseline hypertension grade†

Baseline BMI‡

Comorbid conditions

�

Quintiles calculated using principle component analysis of baseline household wealth survey and were calculated at

the level of the household.
†

Baseline hypertension severity defined by lowest of 3 BP measurements and classified as Grade 1 (BP 140–159/90–
99 mm Hg), Grade 2 (BP 160–179/100–109 mm Hg), Grade 3 (BP �180/110 mm Hg).

‡

BMI categories include underweight (BMI <18.5 kg/m2), normal (BMI 18.5–24.9 kg/m2), overweight (BMI 25–29.9

kg/m2), or obese (BMI �30 kg/m2).
BMIAU
, body
: AbbreviationlistshavebeencompiledforthoseusedinTables1and2:Pleaseverifythatallentriesarecorrect:
mass index; BP, blood pressure; HTN, hypertension.
https://doi.org/10.1371/journal.pmed.1003803.t001
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communities that received the SEARCH intervention (aRR 0.79, 95% confidence interval (CI)
0.64 to 0.97, p = 0.028) (Figs 2 and 3, Table D in S1 Tables). Most participants died of illness
(164/174 [94%] in the intervention group and 218/225 [97%] in the control group; Table E in
S1 Tables).
Mortality increased in a dose-dependent fashion with baseline hypertension severity, and
intervention effect was greater with increasing baseline grade of hypertension (Fig 2, Table D
in S1 Tables). Among those with grade 3 hypertension at baseline (�180/110 mm Hg), 3-year
mortality was 4.9% (22/451) in the intervention group and 7.9% (42/527) in the control group
(aRR 0.62, 95% CI 0.39–0.97, p = 0.038). In sensitivity analyses, relative mortality reductions
were greater when excluding adults �80 years of age (Fig A in S1 Figs, Table F in S1 Tables).
Results were similar when excluding those with prevalent HIV infection (Fig B in S1 Figs,
Table G in S1 Tables), when stratified by sex (Fig C in S1 Figs), and when stratified by country
(Figure D in S1 Figs).

Population-level hypertension control at year 3
Blood pressure was measured at year 3 community health campaigns in 76% of participants in
intervention communities (4,173/5,459) and 75% in control communities (4,113/5,469); there
were no meaningful differences between the participants measured and the participants
missed (Table H in S1 Tables). Overall, 53% of intervention group participants and 44% of
control group participants achieved hypertension control at year 3 (aRR 1.22, 95% CI 1.12 to
1.33, p < 0.001) (Fig 4, Table I in S1 Tables). The intervention both improved hypertension
control and reduced the severity of hypertension at year 3 across all strata of baseline severity,
with larger magnitudes of effect among persons with more severe baseline hypertension
(Table 2, Table J in S1 Tables). Among persons with baseline grade 3 hypertension (�180/110
mm Hg), 79% in the intervention group versus 61% in the control group had reduced hypertension severity after 3 years. The intervention effect on hypertension control was similar by
sex (Fig E in S1 Figs) and when stratified by country (Fig F in S1 Figs).

Hypertension care cascade
In Uganda, 44% of intervention group participants (1,810/4,112) and 35% of control group
participants (1,413/4,030) linked to care within the first year following baseline screening (aRR
1.26, 95% CI 1.11 to 1.42, p = 0.002) (Fig 5), with similar intervention effect stratified by sex
(Fig G in S1 Figs). Among those who linked to care, 42% of intervention group participants
and 22% of control group participants attended at least 1 clinic visit in each of the 3 follow-up
years (aRR 1.97, 95% CI 1.56 to 2.48, p < 0.001; Fig 5, Fig H in S1 Figs). Among those engaged
in care, 56% of intervention group participants and 43% of control group participants had controlled hypertension at year 3 (aRR 1.29, 95% CI 1.03 to 1.63, p = 0.033). Visual examination of
Fig 5 indicates that linkage and care engagement increased with greater baseline hypertension
severity, while hypertension control among those engaged in care decreased with greater
hypertension severity.

Predictors of mortality, hypertension control, and linkage to care
Predictors of mortality among adults with baseline hypertension included age �75 years (aRR
4.69, 95% CI 1.65 to 13.36, p = 0.005), male sex (aRR 1.41, 95% CI 1.09 to 1.82, p = 0.009), baseline HIV infection (aRR 1.87, 95% CI 1.06 to 3.28, p = 0.031), underweight (BMI <18.5 kg/m2;
aRR 1.54, 95% CI 1.22 to 1.94, p < 0.001), and baseline diabetes (aRR 1.98, 95% CI 1.25 to
3.13, p = 0.005) (Fig 6, Table K in S1 Tables). Greater severity of baseline hypertension also
increased risk for mortality, with 42% greater mortality for grade 2 (aRR 1.42, 95% CI 1.09 to
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Fig 2. Cumulative incidence of mortality by year 3. Estimates obtained using 2-stage TMLE to estimate and compare community-level mortality by 3 years. Vertical
error bars depict arm-specific 95% CIs. Baseline hypertension severity defined by lowest of 3 BP measurements and classified as Grade 1 (BP 140–159/90–99 mm Hg),
Grade 2 (BP 160–179/100–109 mm Hg), Grade 3 (BP �180/110 mm Hg). BP, blood pressure; CI, confidence interval; RR, relative risk; TMLE, targeted maximum
likelihood estimation.
https://doi.org/10.1371/journal.pmed.1003803.g002
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Fig 3. Kaplan–Meier curve depicting cumulative incidence of mortality by trial arm. Participants with unknown
year 3 vital status were censored at the time they were last known to be alive.
https://doi.org/10.1371/journal.pmed.1003803.g003

1.85, p = 0.010) and 64% greater mortality for grade 3 (aRR 1.64, 95% CI 1.27 to 2.12,
p < 0.001), compared to baseline grade 1 hypertension.
Persons with greater baseline hypertension severity were at lower risk of achieving hypertension control at year 3 (aRR 0.59, 95% CI 0.55 to 0.64, p < 0.001 for grade 2 and aRR 0.44,
95% CI 0.35 to 0.55, p < 0.001 for grade 3) (Fig I in S1 Figs, Table L in S1 Tables). HIVinfected individuals were more likely to achieve hypertension control than those who were
HIV uninfected at baseline (aRR 1.24, 95% CI 1.15 to 1.33, p < 0.001), while obese individuals
were less likely to achieve hypertension control (BMI �30 kg/m2; aRR 0.84, 95% CI 0.75 to
0.95, p = 0.009).
Linkage to care among participants in Uganda was greater with older age (aRR for age >75
1.71, 95% CI 1.44 to 2.02, p < 0.001), higher baseline hypertension severity (aRR 1.34, 95% CI
1.26 to 1.43, p < 0.001 for grade 2 and aRR 1.63, 95% CI 1.46 to 1.83, p < 0.001 for grade 3),
HIV infection (aRR 2.58, 95% CI 2.01 to 3.30, p < 0.001), and diabetes (aRR 1.34, 95% CI 1.21
to 1.49, p < 0.001) (Fig J in S1 Figs, Table M in S1 Tables).

Discussion
Following community-based hypertension screening that reached 86,078 adults in 32 rural
communities in Uganda and Kenya, implementation of a patient-centered, streamlined hypertension care model integrated with the existing HIV care delivery system was associated with a
21% reduction in 3-year mortality among nonpregnant adults with baseline uncontrolled
hypertension, compared to optimized standard of care in control communities. Mortality
reductions were greatest among those with baseline grade 3 hypertension (blood pressure
�180/110 mm Hg), highlighting the impact over a relatively short time period of identifying
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Fig 4. Hypertension control at year 3. Estimates obtained using 2-stage TMLE to estimate and compare community-level hypertension control at year 3 populationlevel BP measurement. Vertical error bars depict arm-specific 95% CIs. Hypertension control defined as lowest of 3 BPs <140/90 mm Hg at year 3 follow-up
measurement. Baseline hypertension severity defined by lowest of 3 BP measurements and classified as Grade 1 (BP 140–159/90–99 mm Hg), Grade 2 (BP 160–179/
100–109 mm Hg), Grade 3 (BP �180/110 mm Hg). BP, blood pressure; CI, confidence interval; RR, relative risk; TMLE, targeted maximum likelihood estimation.
https://doi.org/10.1371/journal.pmed.1003803.g004
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Table 2. Change in HTN severity from baseline to year 3.
Year 3 HTN Severity
Baseline HTN Severity
Intervention (Overall)

Controlled

Grade 1

Grade 2

Grade 3

Total

2,200 (53%)

1,290 (31%)

511 (12%)

172 (4%)

4,173

Grade 1

1,752 (60%)

862 (29%)

263 (9%)

47 (2%)

2,924 (70%)

Grade 2

351 (39%)

329 (36%)

172 (19%)

54 (6%)

906 (22%)

Grade 3

97 (28%)

99 (29%)

76 (22%)

71 (21%)

343 (8%)

1,764 (43%)

1,371 (33%)

639 (16%)

339 (8%)

4,113

1,475 (52%)

987 (35%)

317 (11%)

65 (2%)

2,844 (69%)

Control (Overall)
Grade 1
Grade 2

227 (26%)

312 (35%)

218 (25%)

123 (14%)

880 (21%)

Grade 3

62 (16%)

72 (19%)

104 (27%)

151 (39%)

389 (9%)

HTN severity defined by lowest of 3 BP measurements and classified as Controlled (BP <140/90 mm Hg), Grade 1 (BP 140–159/90–99 mm Hg), Grade 2 (BP 160–179/
100–109 mm Hg), Grade 3 (BP �180/110 mm Hg). Rows represent baseline HTN severity, and columns represent year 3 HTN severity; both baseline and year 3 BP
measurements were conducted at community health campaigns, and, thus, measurement was independent of engagement with clinical care.
BP, blood pressure; HTN, hypertension.
https://doi.org/10.1371/journal.pmed.1003803.t002

individuals with severe elevations in blood pressure and linking them to a care system that
actively seeks to reduce patient- and clinic-level barriers.
At study baseline, a community-based multidisease model was used to integrate hypertension and diabetes screening into community-wide HIV testing, successfully screening 68% of
126,311 census-enumerated adults for hypertension. As we previously reported, this was
achieved at a marginal cost increase of $1.16 USD per person [27]. Of those identified with

Fig 5. Cascade of hypertension care in 20 communities in Uganda. Figure represents the proportion attaining each cascade step, among those attaining the prior step.
Estimates obtained using 2-stage TMLE to estimate and compare the community-level proportion attaining each cascade step. Vertical error bars depict arm-specific 95%
CIs. Linkage to care defined as �1 visit for hypertension care in the first year after baseline hypertension screening. Engagement in care defined as �1 clinic visit for
hypertension care in each of 3 years of study follow-up. Hypertension control defined as the lowest of 3 BP measurements <140/90 mm Hg at year 3 community-wide
hypertension testing. Baseline hypertension severity defined by lowest of 3 baseline BP measurements and classified as Grade 1 (BP 140–159/90–99 mm Hg), Grade 2 (BP
160–179/100–109 mm Hg), and Grade 3 (BP �180/110 mm Hg). BP, blood pressure; CI confidence interval; HTN, hypertension; RR, relative risk; TMLE, targeted
maximum likelihood estimation.
https://doi.org/10.1371/journal.pmed.1003803.g005
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Fig 6. Predictors of 3-year mortality. Predictors of mortality by study year 3 using multivariable TMLE, with relative risks for each variable compared to reference value.
Horizontal error bars depict predictor-specific 95% CIs. Reference values for relevant categorical variables include female, grade 1 hypertension, age 18–29 years, normal
BMI, baseline HIV uninfected, and baseline absence of diabetes. Baseline hypertension severity defined by lowest of 3 BP measurements and classified as Grade 1 (BP 140–
159/90–99 mm Hg), Grade 2 (BP 160–179/100–109 mm Hg), Grade 3 (BP �180/110 mm Hg). BMI categories include underweight (BMI <18.5 kg/m2), normal (BMI
18.5–24.9 kg/m2), overweight (BMI 25–29.9 kg/m2), or obese (BMI �30 kg/m2). BL, baseline; BMI, body mass index; BP, blood pressure; CI, confidence interval; DM,
diabetes mellitus; HTN, hypertension; TMLE, targeted maximum likelihood estimation.
https://doi.org/10.1371/journal.pmed.1003803.g006
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uncontrolled hypertension, 87% were previously unaware of their diagnosis, consistent with
prior studies demonstrating very low hypertension awareness in SSA [5,6]. Although other
studies have demonstrated feasibility of integrating HIV and NCD community-based screening [28,29], we demonstrate that community-based multidisease testing campaigns can
achieve a high level of population-wide hypertension screening coverage, addressing the critical first step in the hypertension care cascade.
In the context of this population-wide screening, offered in both randomized arms at baseline, we found that a patient-centered chronic care delivery model improved hypertension
control and reduced mortality among adults with uncontrolled hypertension beyond that of
optimized standard care. We previously reported profound population-level health effects of
this care delivery model among HIV-infected persons, including reduced mortality among
those with prevalent HIV infection [17] and men with low CD4 counts [30], improved viral
suppression among those with HIV viremia despite prior attempts at care engagement [31],
reduced maternal-to-child transmission of HIV [32], and decreased incidence of tuberculosis
[17]. Taken together, our findings support the value of integrated patient-centered chronic
care models, when combined with multidisease community-based screening programs, for
improving a wide range of population health outcomes.
Through a patient-centered approach, our intervention targeted multiple barriers along the
hypertension care cascade, improving hypertension diagnosis, linkage to care, and hypertension control. The intervention included introduction to a clinic staff member at the time of
hypertension diagnosis to facilitate relationship-building and promote linkage. At the clinic
and provider levels, the intervention included provider training on providing friendly services
and fostering a welcoming environment, clinic procedures to expedite visits and minimize
patient waiting time, and multimonth medication refills. We have previously reported that
HIV-infected patients identified increased support and access to providers available in our
patient-centered care model as important for improving care engagement [33]; further
research is needed to understand the elements of this care model that were most important for
improving engagement with hypertension care. Our findings build on prior literature demonstrating that patient-centered care models can improve patient engagement in care and health
outcomes [34].
Our findings help narrow the knowledge–implementation gap for translating evidencebased hypertension treatment into practice in SSA. Despite clear evidence of the efficacy of
antihypertensive treatment [7,8], our study is the first, to our knowledge, to demonstrate
reductions in population-level mortality through implementation of an integrated hypertension–HIV chronic care model in SSA. Other clinic-based NCD care models have shown modest improvement in clinic processes or in blood pressure control with task-shifting to
nonphysician health workers in nonintegrated settings [35,36] and with integration of hypertension into HIV care [13–16]; ultimately, multiple models will likely be needed to adapt
hypertension care into different contexts. Interventions that incorporate population-level
community-based NCD screening have been more limited. Outside of SSA, the HOPE 4 trial
recently demonstrated reduction in population-level cardiovascular risk with a communitybased lay health worker–delivered hypertension intervention in Malaysia and Colombia [37].
Our study expands on these findings to demonstrate the effectiveness of a patient-centered
chronic care model that leverages the HIV care system for improving population-level hypertension control and reducing mortality within the context of population-level NCD and HIV
screening.
Although improvements in hypertension treatment were sufficient to reduce mortality,
there are several opportunities for further improvement. First, linkage to care was suboptimal,
though similar to that observed in smaller community-based hypertension screening studies
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[29,38]. Individuals with comorbid HIV linked at much higher rates than those without HIV,
a difference that may be attributable in part to enhanced linkage interventions received by persons with HIV infection, including receipt of a transport voucher at time of diagnosis (both
arms) and a phone call and/or home visit for persons who missed their scheduled intake
appointment (intervention arm only). Interventions to improve linkage among people with
hypertension would likely further reduce mortality beyond what we observed in the SEARCH
study. Second, as previously reported, limited medication supplies intermittently resulted in
shorter duration of medications dispensed than intended, contributing to reduced hypertension control [19]. Improvements in the hypertension medication supply chain, informed by
success with the HIV supply chain, may further improve care engagement and hypertension
control beyond what was achieved in the SEARCH study [39]. Third, treatment algorithms in
SEARCH used sequential addition of single antihypertensive medications, some of which
involved twice daily dosing. Use of once daily fixed-dose combination therapy for hypertension treatment may further improve hypertension control through simplified implementation,
increased treatment efficacy, and improved medication adherence [40]. Finally, engagement
in hypertension care declined over time. Additional research is needed to understand the
determinants of disengagement from hypertension care and areas for possible intervention.
A recent cost-effectiveness analysis found that scale-up of an integrated NCD-HIV intervention similar to SEARCH would avert 116,600 CVD events and 43,600 cardiovascular deaths
across Kenya over the next 15 years and would be highly cost-effective at $860 USD per disability-adjusted life year (DALYAU
) averted
: PleasenotethatDALY
[41]. However, these
hasbeendefinedasdisability
estimates were based on hypertenadjustedlifeyearint
sion costs from nonintegrated care settings that were much higher than costs reported in
SEARCH. We estimate that hypertension care cost an additional $11.39 USD/person/year for
HIV-uninfected persons and $6.29 USD/person/year for HIV-infected persons [42], far lower
than estimates of $77.65 USD/person/year reported from nonintegrated settings that were
used in this cost-effectiveness analysis. Thus, the SEARCH universal screening and streamlined care model may be more cost-effective than previously estimated.
This study had several limitations. First, vital status was assessed among 99% of participants
at the end of the study with broad causes of mortality identified using methods previously
developed (e.g., illness, childbirth, suicide, accident) [43]; however, we were not able to identify
more specific causes of mortality that are known to be associated with hypertension (e.g., myocardial infarction, cerebrovascular accident). Nonetheless, we observed a population-level
reduction in all-cause mortality with implementation patient-centered hypertension treatment
with greater impact among those with more severe baseline hypertension. Second, unavailability of visit data in Kenya precluded us from estimating linkage and care engagement across the
entire study population. Assessment of these process outcomes in 20 communities in Uganda
provided insight into the mechanisms involved in observed reductions in mortality and hypertension control; importantly, the core health outcomes assessed in this analysis (mortality and
hypertension control) were assessed at a population level with high coverage, including among
persons not in care, in all 32 study communities. Third, we were only able to measure linkage
to care at clinics within study communities; thus, linkage to clinics outside of study communities may have been missed. If improvements in care quality due to the patient-centered care
intervention led participants in intervention verus control communities to disproportionately
link to study-supported government clinics rather than to other clinics, our results may overestimate the intervention impact on linkage. Finally, the control condition in our study exceeded
the contemporary standard of hypertension care; thus, our findings likely underestimate the
effects of implementing this population-level multidisease test and treat intervention. Both
control and intervention communities received community-wide hypertension and multidisease screening, substantially increasing hypertension diagnosis. Intervention and control
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community clinics were all government run and received similar levels of staffing support provided by the study in order to ensure that hypertension care was delivered per intended country guidelines in control communities. Medications for hypertension were also provided to
patients free of charge in control communities, concordant with country guidelines but
exceeding conditions in usual practice where patients are usually required to purchase medications. Further research is needed to evaluate implementation strategies to translate the
SEARCH patient-centered chronic care model into routine practice settings.

Conclusions
In conclusion, we found that patient-centered hypertension treatment integrated into the HIV
care delivery system improved all-cause mortality and hypertension control among adults
with uncontrolled hypertension identified through community-based multidisease screening.
Broader, sustained adoption of the SEARCH patient-centered chronic care model is a costeffective way to improve NCD treatment in settings with a high burden of HIV and may result
in greater reduction in CVD and mortality over time than was observed over this 3-year study.
Further, improving community health through implementation of a chronic care model that
integrates NCD and HIV treatment makes important strides toward universal primary healthcare access and achieving Sustainable Development Goals to reduce premature mortality from
NCDs.
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